Influenza
Conditions
Interventions
Two groups:Oseltamivir 150mg twice daily compared with Oseltamivir 225mg twice daily for minimum duration of 10 days
Sponsors
Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Adult patients suffering from influenza requiring mechanical ventilation who require oseltamivir therapy
Exclusion criteria
Exclusion criteria: Pregnant patients and patients with renal failure requiring renal replacement therapy at presentation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| rate of viral clearance over the period of treatment defined as the rate of PCR negativity (i.e. below detection limits) and culture negativity at each of the specimen sites (upper and lower respiratory tract) 5 days after commencement of treatment protocol.; | — |
Secondary
| Measure | Time frame |
|---|---|
| longitudinal viral concentration change in the upper respiratory tract (nasopharyngeal and tracheal samples) from day 0 to day 7 and from lower respiratory tract (BAL samples) between day 3 to day 5 and day 8 to day 10 of oseltamivir treatment.;serial change of respiratory physiological and mechanical parameters (including but not limited to oxygen requirement, lung compliance, Positive End Expiratory Pressure (PEEP) requirement, radiological involvement, and composite severity score),;duration of mechanical ventilator support;ICU length of stay;hospital length of stay;30 days mortality; | — |
Countries
China
Contacts
Public ContactDr. Wai-Tat WONG
Outcome results
None listed